Company intelligence / Profile preview

Affitech

Oslo, Norway

Ownership: Public · AFFI
Development stage: Other

Overview

Lead program AT001/r84 (anti-VEGF antibody) showed strong preclinical efficacy; other programs for oncology and inflammation entered Phase 3 or were discontinued/licensed out by early-mid 2010s; no active clinical development ongoing[4][1][3].

Therapeutic areas: OncologyPulmonologyImmunology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Partnerships

IBC Generium (license for anti-VEGF antibody AT001/r84 in Russia)[1]Epimmune, Inc. (collaborator, discontinued programs)[4]

Beyond the preview

Go deeper on Affitech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affitech.